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ABSTRACT 
Background 
Risk-reducing-salpingectomy & Delayed-Oophorectomy(RRSDO) is being proposed 
as a two-staged approach in place of RRSO to reduce the risks associated with 
premature menopause in high-risk women. We report on the acceptability/attitude of 
UK health professionals towards RRSDO.  
Methods 
An anonymised web-based survey was sent to UK Cancer Genetics Group(CGG) 
and British Gynaecological Cancer Society(BGCS) members to assess attitudes 
towards RRSDO. Baseline characteristics were described using descriptive statistics. 
A chi-square test was used to compare categorical, Kendal-tau-b test for ordinal and 
Mann-Whitney test for continuous variables between two groups. 
Results 
173/708(24.4%) of invitees responded. 71% respondents (CGG=57%/BGCS=83%, 
p=0.005) agreed with the tubal hypothesis for OC, 55% (CGG=42%/BGCS=66%, 
p=0.003) had heard of RRSDO and 48% (CGG=46%/BGCS=50%) felt evidence was 
not currently strong enough for introduction into clinical practice. However, 60% 
respondents’ (CGG=48%/BGCS=71%, p=0.009) favoured offering RRSDO to high-
risk women declining RRSO, 77% only supported RRSDO within a clinical trial 
(CGG=78%/BGCS=76%) and 81% (CGG=76%/BGCS=86%) advocated a UK-wide 
registry. Vasomotor symptoms(72%), impact on sexual function(63%), 
osteoporosis(59%), hormonal-therapy(55%) and subfertility(48%) related to 
premature menopause influenced their choice of RRSDO. Potential barriers to 
offering the two-stage procedure included lack of data on precise level of 
benefit(83%), increased surgical morbidity(79%), loss of breast cancer risk reduction 
associated with oophorectomy(68%), need for long-term follow-up(61%) and a 
proportion not undergoing DO(66%). There were variations in perception between 
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BGCS/CGG members which are probably attributable to differences in clinical 
focus/expertise between these two groups. 
 
Conclusions 
Despite concerns, there is reasonable support amongst UK clinicians to offering 
RRSDO to premenopausal high-risk women wishing to avoid RRSO, within a 
prospective clinical trial. 
 
 
Key Words 
Risk reducing salpingectomy, delayed oophorectomy, RRSDO, BRCA, high-risk, 
ovarian cancer 
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Introduction: 
Ovarian cancer (OC) is the leading cause of death from gynaecological malignancies 
in the UK.[1] 13%-23% of non-mucinous epithelial OC[2-7] have mutations in the 
BRCA1 and BRCA2 genes, which account for most of the known hereditary risk for 
OC. Published meta-analyses have found cumulative breast and ovarian cancer risks 
(until age 70 years) to be: up to 65% and 40% respectively for BRCA1 carriers, and 
up to 49% and 18% respectively for BRCA2 carriers.[8-10] However, higher 
penetrances have been documented in carriers ascertained from high-risk families 
with multiple cancer cases.[11-15] Premenopausal risk reducing salpingo-
oophorectomy (RRSO) is the mainstay of treatment as effectiveness of ovarian 
cancer screening in the high risk population is still not established.[16-18] It is the 
most effective option for preventing tubal/ ovarian cancer, with a hazard ratio (HR) of 
0.21 (95%CI 0.12, 0.39)[19] reported in a recent meta-analysis in known BRCA1 and 
BRCA2 carriers. Although, the benefits of RRSO are significant, decision making is a 
complex process with many women and clinicians concerned over the side effects of 
premature surgical menopause, such as: a higher risk of cardiovascular disease,[20-
22] potential cognitive impairment and Parkinsonism,[23-25] osteoporosis, vasomotor 
symptoms, and detrimental impact on quality of life.[26, 27] Premature menopause 
has been shown to have a mortality impact[28] in low risk women. Risks are higher in 
women who undergo the procedure under the age of 45 and do not take hormone 
replacement therapy (HRT).[27, 28] This has led to high-risk premenopausal women 
too, opting to delay RRSO till after the menopause.[29]  
 
The increasing support, acceptance and awareness of the tubal origins of OC,[30] 
has led to premenopausal risk reducing salpingectomy (RRS) and, subsequently 
delayed oophorectomy (DO) after the menopause as a two staged approach being 
put forward as a management option for reducing OC risk in women at high-risk of 
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familial OC. Based on the supposition that interim RRS provides significant OC risk 
reduction which outweighs the risks, some clinicians advocate use in clinical practice 
in high risk women who refuse RRSO for fear of early menopause.[31, 32]  
 
However, the benefit of a two stage ‘risk reducing salpingectomy delayed 
oophorectomy’ (RRSDO) approach is unproven. It will not prevent cancers that arise 
outside the tube. Available evidence does not adequately elucidate the level of risk 
reduction associated with RRS in this population, the long-term implication of 
salpingectomy on ovarian function and the cost-effectiveness of such an approach. 
Concerns have also been raised that despite advice, a proportion of women may 
delay or not undergo DO following the menopause and it is possible that some of 
these women may develop OC  
 
Despite current literature leaving many questions unanswered a number of centres 
have changed clinical protocols to offer RRSDO.[32, 33] We have tried to generate 
UK wide debate and consensus on this issue by developing a working group and 
involving members of the Cancer genetics Group (CGG) and British Gynaecological 
Cancer Society (BGCS). We report results of a survey undertaken to understand UK 
clinicians’ attitudes towards RRSDO in pre-menopausal women at high risk of familial 
OC and propose a preventative surgical framework/way forward for high risk women 
in the UK.   
 
Methods: 
 
We sent an anonymised web-based survey to members of the UK Cancer Genetics 
Group (CGG) and the British Gynaecological Cancer Society (BGCS) between 
August and September 2014 to assess attitudes towards RRSDO. One reminder 
email was sent approximately 2 weeks after the initial invitation. Both of these are 
6  
UK-wide societies, predominantly comprised of cancer geneticists/genetic 
counsellors (CGG) and surgical gynaecological oncologists (BGCS) respectively.  
 
The 13-item survey included baseline characteristics regarding the respondent’s 
post, specialty, practice setting, years of experience and the number of high-risk 
women encountered in clinical practice.  Questionnaire items covered: agreement 
with the tubal hypothesis for the origin of ovarian cancer (5-item Likert scale- strongly 
agree to strongly disagree); familiarity/awareness with the concept of RRS & DO as a 
risk reducing strategy (‘yes/no’ question); the importance of premature menopause in 
RRSO decision making (5-item Likert scale); the association between oophorectomy 
and subsequent breast cancer risk; views/awareness of factors influencing RRSO 
decision making (tick box options); views/awareness of potential barriers to the 
introduction of RRSDO as a risk reducing strategy based on current literature and the 
high risk groups in whom they would support introduction of RRSDO (‘yes’, ‘no’ and 
‘not sure’ options). Clinicians’ attitudes and willingness to offer RRSDO were 
assessed with a 5-point Likert scale on how strongly they would support introduction 
of RRS & DO into routine practice, offer this to women declining RRSO, and offer this 
within the context of a clinical trial/ registry   Respondents could recheck all answers 
and an optional free text box was also provided for further comments. 
 
Questionnaire development 
The 13-item survey (Supplementary Table 1) was developed in several stages. An 
initial draft survey comprising 23 items was developed by the core study team 
following a literature review. Each question was systematically discussed and 
debated. This was subsequently reviewed by 8 senior clinicians in the fields of 
Cancer Genetics and surgical Gynaecological Oncology.  They gave each item a 
relevance score from 1 (least relevant) to 4 (most relevant) based on their knowledge 
and experience in cancer genetics and working with high risk families. They were 
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also asked to identify any additional questions which they considered important and 
may be missing. A second consensus meeting was held to review responses to the 
initial questionnaire, delete low relevance items and to optimise questionnaire length 
and facilitate compliance. All the items used in the final survey had scores ≥3.1/4.  A 
second pilot of the web-based survey was carried out for readability, ease of use, 
and layout. These processes helped ensure content and face validity. The final 
version was further reviewed/commented on by executive members of the BGCS 
and CGG resulting in further rationalisation to a 13 item questionnaire 
(Supplementary table-1). . 
 
Baseline respondent characteristics were described using descriptive statistics. A 
chi-square test was used to compare categorical variables, Kendal tau-b test to 
compare ordinal variables and t-Test (parametric)/ Mann-Whitney (non-parametric) 
tests to compare continuous variables between two groups. Two-sided P-values are 
reported for all statistical tests. Statistical calculations were performed using SPSS 
22.0. 
 
Results 
 
Of the 708 survey invitations sent, 173 responded, giving a response rate of 24.4% 
(23% (80/348) CGG; 26% (93/360) BGCS).  Baseline characteristics of the 
respondents are tabulated in Table-1. 48% CGG and 87% BGCS respondents were 
consultants while 44% CGG respondents were genetic counsellors.  Of the BGCS 
respondents 83% worked in surgical Gynaecological Oncology and 11% in general 
Obstetrics & Gynaecology.   
 
Prior to completing the questionnaire, only 55% (66% BGCS, 42% CGG, p=0.003) 
respondents had heard of the concept of offering RRSDO in pre-menopausal high-
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risk women who have completed their family. Attitudes of CGG and BGCS 
respondents towards the tubal hypothesis and introduction of RRS & DO are 
described in Table-2. Overall 71% (57% CGG, 83% BGCS, p=0.005) respondents 
agreed/strongly agreed with the hypothesis that a significant proportion of high grade 
serous OC originates from the fallopian tube. 48% respondents agreed that the 
current body of evidence was not strong enough to introduce RRSDO into routine 
clinical practice, whilst 38% were undecided. However, 60% of respondents were in 
favour of offering RRSDO to women who decline RRSO. An overwhelming majority 
(77%) would only support RRSDO within the context of a clinical trial and 81% 
agreed/strongly agreed that there should be a UK-wide registry of all women 
undergoing RRSDO. 44% of CGG and 31% BGCS respondents, disagreed or 
strongly disagreed, that a significant proportion of high-risk women decline/delay 
RRSO due to their concerns about the effects of early surgical menopause. 
Vasomotor symptoms (72%), negative impact on sexual function (63%), osteoporosis 
(59%), need for hormone replacement therapy (55%) and loss of fertility (48%) 
ranked as the top five effects of surgical menopause that influence pre-menopausal 
women considering risk reducing surgery (details in Table-3). Interestingly, there 
were some differences in perception between CGG and BGCS groups. CGG 
members felt survival (p=0.001) and loss of fertility (p=0.003) were more important 
factors while BGCS members believed vasomotor symptoms (p=0.015) to be more 
significant. Additional free text comments highlighted the importance of ‘attachment 
to female organs/loss of femininity’ (n=4) and ‘fear of surgery’ (n=3).  Only 47% 
BGCS compared with 95% of CGG respondents group (p<0.0001) correctly identified 
the 50% reduction in breast cancer risk associated with premenopausal RRSO.   
 
Details of risk categories which may receive support for RRSDO are given in Table-
4.  Overall BGCS members (71%) were significantly more supportive than CGG 
members (48%) of offering RRSDO to women at high risk of familial ovarian cancer 
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(p=0.009). The majority of the respondents thought that there are a number of 
potential barriers to offering RRSDO compared to RRSO (Table-4). Higher surgical 
morbidity, lack of compliance with DO and paucity of cost-effectiveness data were 
felt to be significantly greater limitations by CGG than BGCS members. Other free 
text comments included: lack of awareness of literature (n=5), support for future 
research but questioning the practicality of long term follow up to elucidate level of 
benefit in comparison to RRSO (n=3), dissatisfaction with ‘lack of evidence on the 
magnitude of risk reduction with RRSDO’ (n=3) and restricting RRSDO to women 
who declined RRSO (n=2).  
 
DISCUSSION 
 
This paper for the first time highlights the awareness and views of cancer geneticists, 
genetic counsellors and gynaecological oncologists (clinicians) in the UK regarding 
RRSDO as a risk reducing strategy in women at high risk of familial OC. Our survey 
is broad based and covers the major clinical groups (both genetics clinicians and 
gynaecologists) involved in the management of these women. A small proportion of 
respondents in the survey are general obstetricians & gynaecologists who are 
members of the BGCS and hence have a special interest in gynaecological 
oncology. These include trainees in gynaecological oncology and district general 
hospital leads for gynaecological oncology. Like surgical gynaecological oncologists 
they would be involved in undertaking risk reducing surgery and managing high-risk 
women. We found limited awareness amongst health professionals regarding the 
concept of RRSDO with 45% being unaware of the procedure at the outset. 
Interestingly this lack of awareness was greater amongst the genetics community. 
This figure is also likely to be much higher for general gynaecologists/obstetricians 
who lack a special interest in gynaecological oncology and general practitioners. This 
suggests the need to increase awareness amongst UK clinicians and health 
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professionals, should a trial to explore such an intervention be implemented in the 
future.   
 
Almost half the respondents reported that there was not enough evidence for 
introduction of RRSDO into routine clinical practice. This highlights the awareness 
and importance attached to limitations of this intervention. However, there appeared 
reasonable support (60%) for offering it to premenopausal women declining the gold 
standard RRSO. This is consistent with views of clinicians/groups from other 
countries in favour of providing some form of risk reduction in women who may 
otherwise get none.[32, 34] It has the added advantage of detecting serous tubal 
intraepithelial carcinoma (STIC) / occult invasive cancers in some women[33] 
enabling them to undergo appropriate treatment at an earlier time. The timing of the 
insult/ trigger for development of cancer or shedding of precancerous cells from the 
tube is not known. Hence, early RRS can be of potential benefit. However, this 
should not be undertaken before the family is complete. In addition, the potential long 
term impact of RRS on ovarian function and onset of menopause is not known and 
this should be built into the decision making.  
 
There was overwhelming support for offering RRSDO only within the context of a 
clinical trial (77%) as well as for establishing a UK-wide registry (81%) for all women 
undergoing RRSDO. This predominant view reflects the recognition of the need for 
long term follow-up, given the limited prospective data on efficacy, such as level of 
OC risk reduction, impact on survival, long term ovarian function/menopause and 
importance of ensuring subsequent DO and monitoring attrition. It also provides the 
additional benefit of standardised protocols for the procedure including use of 
positive peritoneal cytology, management of STICs and staging surgery for occult 
disease, as well as the opportunity for bio-banking for translational research. This is 
something the authors are also strongly in favour of and recommend.  
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We found some differences in awareness and attitudes between gynaecological-
oncologists and cancer geneticists/genetic counsellors towards RRSDO. The 
significantly greater support for the tubal hypothesis, the importance of premature 
menopause in decision making and support for offering RRSDO amongst 
gynaecological oncologists (Table-2) probably reflects their role in preforming risk 
reducing  procedures, and counselling/consenting women prior to surgery. The 
differences in perception of factors affecting decision making for risk reducing 
surgery (Table-3) can also largely be explained by the differences in clinical 
focus/expertise between the two groups. Overall, the factors underscored as 
important by UK gynaecologists and geneticists have also been highlighted by 
clinicians elsewhere.[29, 35] Both gynaecologists and geneticists attached much 
lower importance to neurological sequelae and cardiovascular risk towards decision 
making. While data related to neurological consequences are more limited and 
emerging,[24, 25] the impact on higher risk of heart disease is more substantial and 
well established.[20-22] Compared to geneticists, gynaecologists were half as aware 
of the 50% reduction in breast cancer risk with premenopausal RRSO. While a 
number of analyses in the high-risk[19, 36] women have shown this benefit, a recent 
Dutch paper published after this survey[37] underlined methodological deficiencies in 
earlier analyses[36, 38, 39] and reported no benefit of breast cancer risk reduction 
from premenopausal RRSO. However, a key limitation was the short follow-up of 
only 3.2 years. It is possible/likely that any benefit of reduction in breast cancer risk 
will be seen only after a longer period of follow up.  Some of the differences found 
between geneticists and gynaecologists highlight an important issue of potentially 
conflicting information being given out to patients by different groups of clinicians 
involved in their care which can make decision making more confusing for them. This 
is an issue that needs to be addressed. Standardised patient information sheets 
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approved by both the BGCS and CGG, as well as steps to increase 
awareness/education amongst all health professionals are needed. 
 
The significantly greater support amongst gynaecological oncologists for RRSDO in 
all risk categories (Table-4) may be reflective of their experience of treating 
advanced ovarian cancer patients and therefore greater belief/perception of benefit 
of risk reducing procedures as well greater awareness of absolute OC risk amongst 
cancer geneticists and the small absolute risk benefit in some risk categories (Table-
5). The absolute risk of developing OC by the age of 50 years has been found to vary 
from 11% to 22.7% in BRCA1 carriers and 0.4% to 4% in BRCA2 carriers, with risks 
at the higher end of the range reported from families ascertained through genetic 
clinics and lower level risks reported from meta-analysis correcting for ascertainment 
bias.[8, 9, 15, 40-42] Most of this risk occurs after the age of 35 years in BRCA1 and 
after the age of 45 years in BRCA2 carriers. In the UK RRSO is available not only to 
BRCA1/BRCA2 carriers but also to women of unknown mutation status who have 
greater than 10% life time risk of ovarian cancer. The absolute benefit to such 
women will be lower. Table-5 provides the potential benefit of reduction in OC risk for 
various risk categories assuming 40%/50%/60% risk reduction benefit from RRS. 
Most clinicians did not feel that RRSDO should be offered to RAD51C/D carriers. 
This is consistent with limited awareness of newer cancer genes, lack of validated 
precise estimates of ovarian cancer risk for these mutations and current unavailability 
of testing for these on the UK National Health Service (NHS). However, the 
applicability of RRSDO to this cohort may change as more data emerge and testing 
becomes available in clinical practice.  
 
The barriers to introduction of RRSDO found in our survey are consistent with those 
recently highlighted by others.[34, 43, 44] The top ranked barrier was lack of 
evidence of level of risk benefit obtained from RRS. While the tube is an extremely 
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important piece of the puzzle, it does not explain the entire picture.[45, 46] Around 
one-third of STIC/occult invasive lesions detected at RRSO in women at high-risk of 
familial OC occur outside the tube.[47] The precise trigger/rate limiting step for 
carcinogenesis and the natural history of preinvasive STIC lesions are yet to be 
established. CGG members expressed significantly greater concern regarding higher 
surgical morbidity with two procedures and lack of compliance with DO. This may 
reflect the experience of gynaecological oncologists that RRSO is a minimally 
invasive procedure with relatively low complication rate and the awareness/concern 
of cancer geneticists of risk issues including the higher residual ovarian and 
peritoneal cancer risk without DO. With the availability of RRS some women who 
would have undergone RRSO may opt for RRS instead, with a proportion 
subsequently delaying postmenopausal DO or declining to undergo another surgical 
procedure. These women would remain at higher cumulative risk for OC/PC. Of note, 
two-thirds of BRCA carriers in a study from the USA found the risks associated with 
the need for two surgeries, possibility of not lowering ovarian cancer risk, and 
potential disruption of ovarian blood supply to be acceptable.[44] There is need to 
understand the views of high risk women in the UK too.  
 
It is interesting that paucity of cost-effectiveness data did not rank high amongst 
clinicians as a barrier to introduction, though it was more important an issue for CGG 
members. A study from British Columbia using a base case utility score for RRSO of 
0.82 and 0.99 for RRS suggested that RRSDO may remain more cost effective than 
RRSO if the utility score for RRSO is <0.93.[48] However, more recent data than they 
used reports the utility score of RRSO alone to be 0.95[49] which may question the 
comparative cost-effectiveness of RRSDO. In addition the potential impact of some 
women dropping out or not undergoing DO was not incorporated in the analysis. UK 
cost-effectiveness data using NHS costs and National Institute for Health and Clinical 
Excellence (NICE) thresholds which are different from those in North America are 
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lacking. Further studies on cost-effectiveness are needed which compare RRSDO to 
RRSO. 
The response rate of 24.4% may be considered a limitation of the study. However, 
similar levels of response have been reported in other questionnaire based 
surveys,[50, 51] and responses in web/electronic surveys are lower than postal/face-
to-face ones.[52, 53] Besides our survey is broadly representative of both 
gynaecologists and geneticists involved in the care of high risk women in the UK.  
 
Our study highlights reasonable support amongst the UK cancer geneticists/genetic 
counsellors and gynaecological oncologists for offering RRSDO to premenopausal 
high-risk women who decline RRSO. In the absence of prospective data on 
risk/benefit, the general consensus is that it should be provided within the context of 
a research study rather than recommended for routine clinical use. With rising 
awareness of this option, there is increasing demand from charities and patient 
groups (personal communication). Interest amongst BRCA carriers in participating in 
a RRSDO study/trial has been reported.[43, 44] A clinical trial led by LeBlanc[32] is 
currently underway in France, evaluating Radical Fimbriectomy in BRCA1/2 carriers 
(NCT01608074) and one is being initiated at MD Anderson in the USA comparing 
self selected RRSO and RRSDO and screening, with the primary outcome measure 
being patient compliance with DO at 3 year follow up (NCT01907789). A randomised 
trial comparing RRSDO with RRSO does not seem feasible given there is no data to 
support equipoise in outcomes between the two options. Few high-risk women would 
be willing to be randomised as the risks/benefits differ in the two arms. A pragmatic 
way forward would be a prospective UK wide observational cohort study based on a 
standardized nationally acceptable protocol, with a well-designed patient information 
sheet (highlighting pros and cons) and comprehensive evaluation of short and long 
term outcomes. It is important to ensure that pressure to translate preliminary 
research findings into clinical practice does not impede/prevent collection of evidence 
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required to decide whether RRSDO is appropriate and to identify the processes and 
support mechanisms needed to safely deliver such an approach. 
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Table and Figures 
 
Table 1:  Baseline characteristics of survey respondents 
 
 CGG  (n=80) BGCS (n=93) Total 
Response rate    
 23.0%(80/348) 25.8%(93/360) 24.4%(173/708) 
Post    
Consultant Geneticist/ 
Gynaecolgicaloncologist 
46.2% (37) 87.0% (80) 68.0%  (117) 
Genetic Counsellor 43.8% (35) 0 20.3% (35) 
Subspecialty fellow 0 9.8% (9) 15.2% (9) 
Other  10% (8) 3.3% (3) 11 (6%) 
Specialty    
Cancer/Clinical Genetics 92.5% (74) 1.1% (1) 43.4% (75) 
Surgical GO 3.8% (3) 82.8% (77) 46.2% (80) 
General O&G 0 10.8% (10) 5.8% (10) 
Other 4% (3) 5% (5) 4.6% (8) 
Years in Specialty    
Mean (SD) 12.9 (6.7) 13.9 (8.9) 13.4 (7.9) 
Practice setting    
Tertiary Cancer Centre 10.0% (8) 62.4% (58) 38.2% (66) 
Regional Genetics 
Centre 
78.8% (63) 0% 36.4% (63) 
University Teaching 
Hospital 
8.8% (7) 17.2% (16) 13.3% (23) 
District General Hospital 0 20.4% (19) 11.0% (19) 
Other 3% (2) 0 1% (2) 
No. of high-risk 
women/year 
   
None 2.5% (2) 3.3% (3) 2.9% (5) 
<20 15.2% (12) 60.9% (56) 39.8% (68) 
21-50 50.6% (40) 27.2% (25) 38.0% (65) 
51-100 22.8% (18) 7.6% (7) 14.6% (25) 
>100 8.9% (7) 1.1% (1) 4.7% (8) 
Missing   1.2% (2) 
 
 
 
CGG- Cancer Genetics Group; BGCS- British Gynaecological Cancer Society, 
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Table-2: Attitudes of CGG and BGCS members towards introduction of Risk reducing salpingectomy and Delayed Oophorectomy 
(RRSDO) 
 
  Total Cohort (BGCS and CGG) %(n)   
Survey Item Strongly disagree Disagree Neither agree or disagree Agree Strongly Agree   
Current body of evidence strong 
enough to introduce RRS DO 
into routine clinical practice* 
11.6% (20) 36.6% (63) 38.4% (66) 12.2% (21) 1.2% (2)   
RRS DO should only be offered 
within the context of a clinical 
trial* 
0.6% (1) 5.2% (9) 17.4% (30) 45.9% (79) 30.8% (53)   
  CGG %(n) BGCS %(n)   
Survey Item 
Strongl
y 
disagre
e 
Disagre
e 
Neither 
agree 
or 
disagre
e 
Agre
e 
Strongl
y Agree 
Strongl
y 
disagre
e 
Disagre
e 
Neither 
agree 
or 
disagre
e 
Agre
e 
Strongl
y Agree 
P value 
(Kendall'
s tau-b) 
I support the hypothesis that a 
significant proportion of high 
grade serous cancers (HGSC) of 
the ovary probably originate 
from the fallopian tube? 
0 3.8% (3) 38.8% (31) 
46.2
% 
(37) 
11.3% 
(9) 5.4% (5) 1.1% (1) 
10.9% 
(10) 
45.7
% 
(42) 
37.0% 
(34) <0.005  
Significant proportion of 
premenopausal high risk women 
decline RRSO due to their 
concerns regarding early 
menopause. 
5.0% (4) 38.8% (31) 
25.0% 
(20) 
23.8
% 
(19) 
7.5% (6) 3.3% (3) 27.2% (25) 
19.6% 
(18) 
43.5
% 
(40) 
6.5% (6) 0.03 
I would support offering this 
proposal to women who 
decline/wish to delay risk 
reducing bilateral salpingo-
2.5% (2) 11.4% (9) 
38.0% 
(30) 
45.6
% 
(36) 
2.5% (2) 1.1% (1) 12.0% (11) 
16.3% 
(15) 
66.3
% 
(61) 
4.3% (4) 0.009 
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oophrectomy (RRSO). 
Premenopausal women with a 
past history of breast cancer 
could be offered RRS and DO 
5.1% (4) 21.8% (17) 
46.2% 
(36) 
26.9
% 
(21) 
0 8.7% (8) 42.4% (39) 
23.9% 
(22) 
21.7
% 
(20) 
3.3% (3) 0.033 
There should be a UK wide 
registry of all women undergoing 
risk reducing salpingectomy 
0 3.8% (3) 20.0% (16) 
47.5
% 
(38) 
28.7% 
(23) 0 4.3% (4) 9.8% (9) 
41.3
% 
(38) 
44.6% 
(41) 0.022 
 
*Responses of CGG and BGCS groups were not significantly different for these variables  
 
BGCS- British Gynaecological Cancer Society, CGG- Cancer Genetics Group, RRS- Risk Reducing Salpingectomy, RRSDO- Risk Reducing 
Salpingectomy and Delayed Oophorectomy, RRSO- Risk Reducing Salpingo-oophorectomy, 
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Table 3- Effects of surgical menopause that influence decision making of pre-
menopausal women regarding risk reducing surgery 
 
  Overall (n=172) 
CGG  
(n=80) 
BGCS 
(n=92) 
P 
value 
(Chi 
Sq) 
Cognitive Decline 19.8% (34) 
15.0% 
(12) 
23.9% 
(22) 0.143 
Increased risk of neurological 
disorders 
3.5% 
(6) 2.5% (2) 4.3% (4) 0.51 
Increased cardiovascular risk 19.2% (33) 
23.8% 
(19) 
15.2% 
(14) 0.156 
Osteoporosis 59.3% (102) 
65.0%  
(52) 
54.3% 
(50) 0.156 
Negative impact on sexual 
functioning 
62.2% 
(107) 
62.5% 
(50) 
62.0% 
(57) 0.942 
Need to take HRT until age 50 55.2% (95) 
58.8% 
(47) 
52.2% 
(48) 0.387 
Vasomotor symptoms 71.5% (123) 
62.5% 
(50) 
79.3% 
(73) 0.015 
Potential survival impact 27.3% (47) 
40.0% 
(32) 
16.3% 
(15) 0.001 
Loss of fertility 47.7% (82) 
60.0% 
(48) 
37.0% 
(34) 0.003 
 
 
 
 
CGG- Cancer Genetics Group; BGCS- British Gynaecological Cancer Society, HRT- 
hormone replacement therapy 
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Table 4- Comparison of CGG and BGCS support for RRSDO by risk category 
and barriers to offering RRSDO 
 
 
Comparison of 
CGG and BGCS 
respondents 
Yes % (n) No % (n) Not Sure % (n) 
P value 
(Chi 
Sq) 
Support for 
offering RRS & 
DO in mutation 
carriers at high 
risk of familial 
ovarian cancer 
CGG BGCS CGG BGCS CGG BGCS   
BRCA1 (n=168) 31.6% (24/76) 
60.9% 
(56/92) 
32.9% 
(25/76) 
25.0% 
(23/92) 
35.5% 
(27/76) 
14.1% 
(13/92) <0.0005 
BRCA2  (n=166) 34.7% (26/75) 
60.5% 
(55/91) 
26.7% 
(20/75) 
24.2% 
(22/91) 
38.7% 
(29/75) 
15.4% 
(14/91) 0.001 
RAD51 (n=161) 9.5% (7/74) 
19.5% 
(17/87) 
29.7% 
(22/74) 
16.1% 
(14/87) 
60.8% 
(45/74) 
64.4% 
(56/87) 0.047 
UMS 10% risk 
(158) 
19.4% 
(14/72) 
37.2% 
(32/86) 
23.6% 
(17/72) 
27.9& 
(24/86) 
56.9% 
(41/72) 
34.9% 
(30/86) 0.012 
 Potential barriers 
to offering RRS & 
DO 
CGG BGCS CGG BGCS CGG BGCS   
Risk reduction only 
proven with RRSO 
(n=171) 
77.5% 
(62/80) 
72.5% 
(66/91) 
5.0% 
(4/80) 
12.1% 
(11/91) 
17.5% 
(14/80) 
15.4% 
(14/91) 0.26 
Precise level of risk 
reduction not 
established 
(n=171) 
83.8% 
(67/80) 
82.4% 
(75/91) 
6.2% 
(5/80) 
7.7% 
(7/91) 
10.0% 
(8/80) 
9.9% 
(9/91) 0.934 
Long term follow 
up needed for DO 
(n=167) 
62.3% 
(48/77) 
60% 
(54/90) 
19.5% 
(15/77) 
23.3% 
(21/90) 
18.2% 
(14/77) 
16.7% 
(15/90) 0.828 
Confusion and 
additional stress 
for patients 
(n=168) 
70.1% 
(54/77) 
57.1% 
(52/91) 
16.9% 
(13/77) 
26.4% 
(24/91) 
13.0% 
(10/77) 
16.5% 
(15/91) 0.206 
Increased surgical 
morbidity as 2 
procedures needed 
(n=171) 
83.5% 
(66/79) 
75.0% 
(69/92) 
3.8% 
(3/79) 
22.8% 
(21/92) 
12.7% 
(10/79) 
2.2% 
(2/92) <0.0005 
Some patients may 
not undergo DO 
(n=167) 
76.6% 
(59/77) 
57.8% 
(52/90) 
9.1% 
(7/77) 
25.6% 
(23/90) 
14.3% 
(11/77) 
16.7% 
(15/90) 0.013 
Loss of benefit of 
breast cancer risk 
reduction (n=167) 
65.8% 
(52/79) 
70.5% 
(62/88) 
10.1% 
(8/79) 
21.6% 
(19/88) 
24.1% 
(19/79) 
8.0% 
(7/88) 0.005 
Cost effectiveness 
not known (n=165) 
57.9% 
(44/76) 
39.3% 
(35/89) 
19.7% 
(15/76) 
52.8% 
(47/89) 
22.4% 
(17/76) 
7.9% 
(7/89) <0.0005 
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CGG- Cancer Genetics Group; BGCS- British Gynaecological Cancer Society, 
RRSDO- Risk Reducing Salpingectomy and Delayed Oophorectomy, RRSO- Risk 
Reducing Salpingo-oophorectomy, DO- Delayed Oophorectomy, UMS- unknown 
mutation status 
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Table-5: Potential benefit of reduction in OC risk with RRS for various risk 
categories[8, 9, 15, 40-42] 
 
Risk 
Category 
Total 
OC Risk 
OC Risk 
to 50 
years 
Reduction in 
OC risk till 50 
years with 
40% benefit 
of RRS 
Reduction in 
OC risk till 50 
years with 
50% benefit 
of RRS 
Reduction in 
OC risk till 50 
years with 
60% benefit 
of RRS 
BRCA1 40%-60% 11-22.7% 4.4-9.1% 5.5-11.4% 6.6-13.6% 
BRCA2 18-27% 0.4-4% 0.16-1.6% 0.2-2% 0.24-2.4% 
UMS 10% 2.50% 1% 1.25% 1.5 
FDR 
BRCA1 20-30% 5.5-11.4% 2.2-4.6% 2.8-5.7% 3.3-6.8% 
SDR 
BRCA1 10-15% 2.8-5.7% 1.12-2.3% 1.4-2.9% 1.7-3.4% 
FDR 
BRCA2 9-13.5% 0.2-2% 0.08-0.8% 0.1-1% 0.12-1.2% 
SDR 
BRCA2 4.5-6.8% 0.1-1% 0.04-0.4% 0.05-0.5% 0.06-0.6% 
 
 
FDR- first degree relative, SDR- second degree relative, UMS- Unknown mutation 
status, OC- ovarian cancer, RRS- risk reducing salpingectomy 
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